Emergent BioSolutions (EBS) Tops Q4 EPS by 23c
Tweet
Share
E-mailGet Alerts EBS Hot Sheet
Price: $8.18 +0.49%
EPS Growth %: -31.3%
Financial Fact:
Research and development: 27.19M
Today's EPS Names:
CCEL, SLP, TMQ, More
EPS Growth %: -31.3%
Financial Fact:
Research and development: 27.19M
Today's EPS Names:
CCEL, SLP, TMQ, More
Join SI Premium – FREE
Emergent BioSolutions (NYSE: EBS) reported Q4 EPS of $4.50, $0.23 better than the analyst estimate of $4.27. Revenue for the quarter came in at $723.2 million versus the consensus estimate of $691.36 million.
For earnings history and earnings-related data on Emergent BioSolutions (EBS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Key things to know ahead of SK Hynix’s blockbuster US listing
- Angi Inc. names new chief accounting officer after resignation
- Simulations Plus (SLP) Tops Q3 EPS by 7c
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
